Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinical outcomes for RPL patients pursuing expectant management stratified by AMH level

From: Antimullerian hormone is a predictor of live birth in patients with recurrent pregnancy loss

Outcomes by AMH level: (n = 155 patients) Age (Mean ± SD) Pregnancies per patient, N (%) LBR per pregnancy, N (%) CMR per pregnancy, N (%) Time to Pregnancy, months (Mean ± SD)
AMH < 0.5 (n = 28) 37.9 ± 4.0 14 (50%) 5 (36%) 9 (64%) 4.8 ± 3.7
AMH 0.5–0.99 (n = 19) 36.4 ± 3.1 14 (74%) 6 (43%) 8 (57%) 4.8 ± 2.7
AMH 1–1.99 (n = 41)* 35.3 ± 6.2 30 (73%) 17 (57%) 12 (40%) 3.9 ± 2.2
AMH 2–2.99 (n = 24) 35.0 ± 3.9 16 (67%) 12 (75%) 4 (25%) 4.6 ± 2.3
AMH ≥ 3 (n = 43) 33.7 ± 3.4 29 (67%) 21 (72%) 8 (28%) 4.6 ± 3.3
  1. *1 pregnancy was terminated for XYY karyotype on amniocentesis